PP
Piramal Pharma Limited
PPLPHARMA.BO · BSE
₹200.75 +3.00% (+₹5.85)
1M -11.27%
Market Cap ₹258.6B
P/E Ratio -
Div. Yield -
ROE 3.86%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
31 /100
Expensive P/FCF 56.64x
P/B 3.17x
EV/EBITDA 23.92x
Growth
43 /100
Stable Rev. growth 11.87%
Book val. growth 6.66%
EPS growth 39.63%
Profitability
27 /100
Weak FCF margin 4.96%
Op. margin 1.66%
Gross margin 35.75%
Quality
0 /100
Poor ROE 3.86%
ROA N/A
Asset turnover N/A
Debt
78 /100
Low Int. coverage 0.65x
Net debt/EBITDA 0.00x
Debt/Equity 0.00x
Stability
45 /100
Moderate Profitable years 2
EPS volatility 267.82%
Beta 0.34x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PPLPHARMA.BO
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Peter Daniel DeYoung
Employees
7,120
Headquarters
Mumbai
Upcoming events
11 NOV
Earnings
Upcoming earnings report